Moberg Pharma AB (publ)
MOB
Rank in Stocks
#22782
Moberg Pharma AB (publ) functions as a pharmaceutical company, dedicated to... Moberg Pharma AB (publ) functions as a pharmaceutical company, dedicated to both crafting and globally marketing medical solutions throughout Europe, the United States, and various international territories. A notable product within its development portfolio is MOB-015, a treatment designed for nail fungus, which has successfully concluded its Phase III clinical trials. Established in 2006, this enterprise is headquartered in Bromma, Sweden. It was previously known as Moberg Derma AB (publ) until its rebranding to the current name in May 2013.
Share Price
$1.05
Last synced: 2026-11-09
Market Cap
$49.77M
Change (1 day)
0.34%
Change (1 year)
-2.94%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Moberg Pharma AB (publ) (MOB)
Category
Healthcare
EPS for Moberg Pharma AB (publ) (MOB)
EPS as of June 2026 TTM: $-0.05
According to Moberg Pharma AB (publ)'s latest financial reports, its current EPS (TTM) is $-0.05. At the end of 2025 the company had an EPS of $-0.06, an increase over its 2024 EPS of $-0.61.
EPS history for Moberg Pharma AB (publ) from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.05 | -22.67% |
| 2025 | $-0.06 | -89.71% |
| 2024 | $-0.61 | 363.66% |
| 2023 | $-0.13 | -0.38% |
| 2022 | $-0.13 | -50.73% |
| 2021 | $-0.27 | -65.91% |
| 2020 | $-0.79 | -210.12% |
| 2018 | $0.72 | 6.92% |
| 2017 | $0.67 | -68.64% |
| 2016 | $2.13 | 17.06% |
| 2015 | $1.82 | 73.44% |
| 2014 | $1.05 | -178.59% |
| 2013 | $-1.34 | -126.47% |
| 2012 | $5.05 | -596.99% |
| 2011 | $-1.02 | -84.27% |
| 2010 | $-6.46 | -39.30% |
| 2009 | $-10.65 | -33.82% |
| 2008 | $-16.09 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -14,111.64% |
DE
|
|
| $6.08 | -13,198.28% |
DE
|
|
| $1.55 | -3,441.81% |
JP
|
|
| $3.66 | -7,987.93% |
CH
|
|
| $0.45 | -1,069.83% |
IL
|
Questions about Moberg Pharma AB (publ)'s earnings per share (EPS)
What is Moberg Pharma AB (publ)'s earnings per share (EPS)?
Moberg Pharma AB (publ)'s earnings per share (EPS) over the last twelve months is $-0.05, as of Jun 2026.
What was Moberg Pharma AB (publ)'s earnings per share (EPS) in 2025?
In 2025, Moberg Pharma AB (publ)'s earnings per share (EPS) was $-0.06, compared with $-0.61 in 2024.
How has Moberg Pharma AB (publ)'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Moberg Pharma AB (publ)'s earnings per share (EPS) was highest in 2025 ($-0.06) and lowest in 2020 ($-0.79).
How does Moberg Pharma AB (publ)'s earnings per share (EPS) compare with similar companies?
Moberg Pharma AB (publ)'s earnings per share (EPS) ($-0.05) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.